Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1beta, and nuclear factor kappaB in trinitrobenzene sulphonic acid induced colitis in rats.
OBJECTIVE
Butyrate enemas have been shown to be effective in treatment of ulcerative colitis, but the mechanism of the effects of butyrate is not totally known. This study evaluates effects of topical treatment of sodium butyrate (NaB) and 5-aminosalicylic acid (5-ASA) on the expression of trefoil factor 3 (TFF3), interleukin 1beta (IL1beta), and nuclear factor kappaB (NFkappaB) in trinitrobenzene sulphonic acid (TNBS) induced colitis in rats.


METHODS
Distal colitis was induced in male Wistar rats by colonic administration of TNBS and colonically treated with NaB, 5-ASA, combination of NaB and 5-ASA, and normal saline for 14 consecutive days. Colonic damage score, tissue myeloperoxidase (MPO) activity, TFF3 mRNA expression, serum IL1beta production, and tissue NFkappaB expression were determined, respectively.


RESULTS
Treatment of NaB, 5-ASA, and the combination improved diarrhoea, colonic damage score, and MPO activities, increased TFF3 mRNA expression, and decreased serum IL1beta production and tissue NFkappaB expression. The combination therapy of NaB and 5-ASA had better effects than any other single treatment.


CONCLUSIONS
The combination of topical treatment of NaB and 5-ASA was effective for relieving and repairing colonic inflammation and the effects were related to stimulation of TFF3 mRNA expression and down-regulation of IL1beta production and NFkappaB expression.
Song
M
M
Department of Internal Medicine, Zhongnan Hospital, Donghu Road 169, Wuhan 430071, Hubei Province, People's Republic of China.
Xia
B
B
Li
J
J
D000287:Administration, Topical; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D002087:Butyrates / Q000008:administration & dosage*; D003092:Colitis / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism; D007375:Interleukin-1 / Q000378:metabolism*; D008297:Male; D019804:Mesalamine / Q000008:administration & dosage*; D016328:NF-kappa B / Q000378:metabolism*; D009479:Neuropeptides / Q000378:metabolism*; D009195:Peroxidase / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013451:Sulfonic Acids / Q000633:toxicity; D000071165:Trefoil Factor-3; D014301:Trinitrobenzenes / Q000633:toxicity
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002087:Butyrates; D007375:Interleukin-1; D016328:NF-kappa B; D009479:Neuropeptides; D012333:RNA, Messenger; D013451:Sulfonic Acids; C099037:TFF3 protein, rat; D000071165:Trefoil Factor-3; D014301:Trinitrobenzenes; C025941:trinitrofluorobenzene; D019804:Mesalamine; D009195:Peroxidase